Have confidence in your investment. You're in a phenomenal company on the ground floor. I expect this investment to generate a lot of wealth for those who have the sense to not sell too early for quick profits. The Covid business is only part of the great assets being brought to market. Videssa and Lympro will be late 2022 and 2023 and are well worth remaining invested for.

If you get a chance, listen to the Todos conference call from this afternoon. There's a wealth of information there about what's going on in the background.

You might particularly like the question posted about the RS and uplist. (wink, wink). Bad experience with the Amarantus RS, which is why the question was asked to clarify how this one would be different.